IL142539A0 - Inhibitors of platelet activation and recruitment - Google Patents

Inhibitors of platelet activation and recruitment

Info

Publication number
IL142539A0
IL142539A0 IL14253999A IL14253999A IL142539A0 IL 142539 A0 IL142539 A0 IL 142539A0 IL 14253999 A IL14253999 A IL 14253999A IL 14253999 A IL14253999 A IL 14253999A IL 142539 A0 IL142539 A0 IL 142539A0
Authority
IL
Israel
Prior art keywords
recruitment
inhibitors
platelet activation
platelet
activation
Prior art date
Application number
IL14253999A
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL142539A0 publication Critical patent/IL142539A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14253999A 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment IL142539A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10458598P 1998-10-16 1998-10-16
US10746698P 1998-11-06 1998-11-06
US14901099P 1999-08-13 1999-08-13
PCT/US1999/022955 WO2000023459A1 (en) 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment

Publications (1)

Publication Number Publication Date
IL142539A0 true IL142539A0 (en) 2002-03-10

Family

ID=27379766

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14253999A IL142539A0 (en) 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment

Country Status (7)

Country Link
EP (1) EP1123306A4 (en)
JP (1) JP2002527096A (en)
AU (2) AU772460B2 (en)
CA (1) CA2345382A1 (en)
IL (1) IL142539A0 (en)
NZ (1) NZ511488A (en)
WO (2) WO2000023459A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264809B1 (en) 1998-10-16 2007-09-04 Immunex Corporation Methods of inhibiting platelet activation and recruitment
JP5550799B2 (en) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド TWEAK antagonists and TWEAK receptor antagonists and their use to treat immunological disorders
GB9914326D0 (en) * 1999-06-18 1999-08-18 Rademacher Group Limited Materials and methods relating to the diagnosis and treatment of pre-eclampsia
WO2002014369A2 (en) * 2000-07-24 2002-02-21 Attenuon, Llc Human kininogen d5 domain polypeptides and their use
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
WO2003052121A2 (en) * 2001-12-17 2003-06-26 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
EP2138575B8 (en) * 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
CN102793921A (en) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 Methods for treating tweak-related conditions
JP2006508056A (en) 2002-08-28 2006-03-09 イミュネックス・コーポレーション Compositions and methods for treating cardiovascular disease
AU2003266081A1 (en) 2002-09-13 2004-04-30 Universite Laval Nucleoside triphosphate diphosphohydrolase (ntpdase 8) and uses thereof
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1733045A4 (en) 2004-02-27 2008-08-13 Apt Therapeutics Inc Design and therapeutic use of adpase enhanced apyrases
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
ES2432564T3 (en) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Treatment and evaluation of inflammatory disorders
ES2507069T3 (en) * 2005-05-27 2014-10-14 Biogen Idec Ma Inc. TWEAK binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
DE102006046410A1 (en) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Medicaments for the prophylaxis or treatment or diagnosis of ischemic diseases
GB201522541D0 (en) * 2015-12-21 2016-02-03 Inst Research In Biomedicine Compositions
CN108203457B (en) * 2016-12-20 2022-09-06 山西医科大学 Antithrombotic small peptide omega KWR for targeted inhibition of platelet aggregation
EP3424957A1 (en) * 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
UY38299A (en) * 2018-07-18 2020-02-28 Novartis Ag SOLUBILIZED APIRASES, METHODS AND USES
WO2024023746A1 (en) * 2022-07-29 2024-02-01 Novartis Ag Improved production of cd39 variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
CU22222A1 (en) * 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
CA2216445A1 (en) * 1995-03-24 1996-10-03 Novartis Ag Gene therapy for transplantation and inflammatory or thrombotic conditions
AU5265296A (en) * 1995-04-10 1996-10-30 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology

Also Published As

Publication number Publication date
CA2345382A1 (en) 2000-04-27
NZ511488A (en) 2003-10-31
EP1123306A4 (en) 2002-07-03
AU6411599A (en) 2000-05-08
WO2000023094A2 (en) 2000-04-27
WO2000023459A1 (en) 2000-04-27
AU772460B2 (en) 2004-04-29
JP2002527096A (en) 2002-08-27
WO2000023094A3 (en) 2000-07-27
AU6425699A (en) 2000-05-08
EP1123306A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
IL142539A0 (en) Inhibitors of platelet activation and recruitment
IL128739A0 (en) Inhibition of blood platelet aggregation
IL127873A0 (en) Amidinoindoles amidinoazoles and analogs thereof as inhibitors of factor xa and of thrombin
EP1009415A4 (en) INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
HUP0104379A3 (en) New crystalline form of omeprazole and medicament containing it
PL328868A1 (en) Inhibitors of pharnesil protein transferase
GB9800795D0 (en) Prevention of multiple use of limited use devices
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
HUP0100366A3 (en) Homopolymers and copolymers of ethylene and applying them
GB9227026D0 (en) Dual inhibitors of no synthase and cycloosygenase
IL122813A0 (en) Thrombin inhibitors their preparation and use
PL341335A1 (en) Combination of ace and mmp inhibitors
EP0806958A4 (en) Inhibition of platelet binding
GB9809869D0 (en) Inhibition of protein kinases
PL334517A1 (en) Clavulate and one or more of exicipients containing granules
GB9828296D0 (en) Intumescent downlighter cover and method of manufacturing same
GB9930659D0 (en) Inhibitors of complement activation
EP0983958A4 (en) Treadboard device of man-conveyer and man-conveyer
ZA983065B (en) Inhibitors of protein farnesyltranferase
PL341222A1 (en) Substitute derivatives of isoquinoline and their application as anticonvulsants
PL342733A1 (en) Biocement of improved properties
EP1098659A4 (en) Libraries of polyhydroxamates and their analogs
HUP9800146A3 (en) Thalidomide-derivatives and use of them
EP1140121A4 (en) Cryogranulation of activated protein c